1. Pharma IQ is Pleased to Announce Now in it’s 3rd Year Biobanking has welcomed:
The Latest in Europe’s Leading
Over 200 Attendees from
Commercially Focused
Global
Over 140 Different Organisations
“ In such a topically
Biobanking
diverse area, IQPC
delivered a top
class agenda with “
speakers and
2O1O
delegates to match
Conference: 28th - 29th September 2010
Workshop Day: 27th September 2010
Qiagen
Venue: Thistle Marble Arch, London, UK
Advancing International R&D Through 17 world-renowned speakers:
Effective Sample Management and INTERNATIONAL ADVISORY BOARD:
Global Biobanking Harmonisation Peter Riegman, President, ISBER
TOP 3 Reasons to attend Europe’s leading
industry forum:
Björn Dahllöf, Global Biobank
Head, AstraZeneca
1. Exclusive access to 17 expert biobanking speakers including
7 must see brand new industry case studies! Aleks Davis, Head of Biological
2. Unparalleled networking opportunities across 3 days Sample Management, Eli Lilly
including exclusive evening drinks reception to make
new contacts and benchmark with your peers Manuel Morente, Head of Tumour Bank Unit,
Spanish National Cancer Centre
3. Join the debate on LinkedIn to be part of the largest
industry-focused biobanking event before it even takes place! Glyn Stacey, Director, UK Stem Cell Bank
Mark Divers, Head of Biobank, Karolinska Institute
Attending Biobanking 2010 will ensure you can: Amelia Wall Warner, Head of Clinical
Establish and develop an efficient global biobank network Pharmacogenomics and Clinical Specimen
with tips from Björn Dahllöf, Global Biobank Head, AstraZeneca Management, Merck Research Laboratories
Recover costs more effectively with insights on making better Andreas Koehler, Global Head Clinical
use of available resources from Heather Thorne, KConFab
Manager, Peter MacCallum Cancer Centre Pharmacogenetics, Boehringer-Ingelheim
Expand your sample collection and operating potential with Laurie Overton, Manager, Fermentation Facility,
the latest ISBER and BBMRI plans for future global biobank GlaxoSmithKline
harmonisation and standardisation from Peter Riegman and
Manuel Morente Arndt Schmitz, Leader of Biobank,
Refine the QC of your SOPs to ensure high quality samples for Bayer-Schering
identification of new targets for drug discovery and development Gerardo de Pierro, Sample Management
research with Aleks Davis, Head of Biological Sample and Logistics Manager, Novartis
Management, Eli Lilly
Improve drug efficacy by integrating biobanking into industry Chris Womack, Principal Clinical
biomarker research to identify new biomarkers from your samples: Histopathologist, AstraZeneca
discussion led by Arndt Schmitz, Biobank Leader, Bayer-Schering
Rivka Ravid, Senior Scientist and Advisor,
Royal Dutch Academy of Sciences
4 Exclusive Interactive Pre-Conference Workshops:
A: Technology Spotlight: Real Solutions for Biobanking Gerry Thomas, Professor of Molecular
B: Optimising Your Operating Efficiency with an Effective IT Infrastructure Pathology, Imperial College London
C: Potentials and Pitfalls in Establishing a Global Network to Identify Aoife McDermott, Senior Medical Scientist,
Biospecimens for Research Adelaide and Meath Hospital
D: Building an Internal Pharma Biobank to support Drug Discovery and
Development Heather Thorne, National kConFab Manager,
See inside for more details and package discounts… Peter MacCallum Cancer Centre
Jane Rogan, Biobank Business Manager,
Visit: www.globalbiobanking.com Manchester Cancer Research Centre
Sponsors &
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk
Exhibitors

2. Pre-Conference Workshops 27 September 2010
WORKSHOP A WORKSHOP B
09:00 - 12:00 12:15 - 15:15
Technology Spotlight: Real Solutions for Biobanking Optimising Your Operating Efficiency with an
Effective IT Infrastructure
Technology within biobanking can be a successful solution to improve the
operating efficiency of your biobank, with some of the most successful Many new biobanks and those wishing to expand their capacity and
technologies including sample tracking and tracing, automation, cryo service ability rapidly and effectively have identified that one of the
and ambient storage, integrated IT solutions and many more. Key topics key requirements is having an excellent, fully-integrated, flexible and
for this workshop will include: customisable IT solution at the core of their system. In this interactive
• Existing technologies in the market for sample tracking technologies session:
• Existing technologies in the market for specimen storage • Discover how a smart IT solution can vastly increase the efficiency of
• Which existing technologies are most effective and why your biobank
• What are the next steps from all parties to ensure that these • Improve the quality of your services with effective sample management
technologies do not become obsolete as quickly as others in the past • Widen your client base by providing more information about samples
and in greater detail
Please visit www.globalbiobanking.com for more details. • Manage all your sample data in one simple, easy-to-use database
Please visit www.globalbiobanking.com for more details.
WORKSHOP C WORKSHOP D
15:30 - 18:30 18:45 - 21:45
Potentials and Pitfalls in Establishing a Global Building an Internal Pharma Biobank to support
Network to Identify Biospecimens for Research Drug Discovery & Development
This workshop presents and provides the basic concepts, current and This interactive session allows you to share experiences and discuss
future use of a global network aiming at identifying biospecimens for aspects of establishing an efficient internal global biobank. Examples will
research. The workshop deals with the following issues: be given from the AstraZeneca Biobank. Topics for discussion include:
• Challenges and the difficulties for the rare disease Global community • The use of human tissue for drug discovery & development
to obtain sufficient amounts of biospecimens for basic and clinical • Sources, acquisition and external collaborations
research • Ethical and regulatory considerations
• The need for collaborative and novel approaches • Establishing a global network that facilitates coordination
• The use of patient registries to increase procurements of rare disease • Building an internal infrastructure
biospecimens • Looking at the challenges ahead
• The urgent need for linking every patient registry with a biorepository
• The need for global rare disease network to facilitate sharing and Facilitated by: Björn Dahllöf, Global Biobank Head, AstraZeneca
collaboration among all stakeholders. Chris Womack, Principal Clinical Histopathologist, AstraZeneca
Facilitated by: Rivka Ravid, Senior Scientist and Advisor, Royal Dutch Björn Dahllöf, Director in “Discovery Enabling
Academy of Sciences; Capabilities and Sciences (DECS) / Translational
Heather Thorne, National kConFab Manager, Peter MacCallum Cancer Centre Sciences”, is the Global Head of the recently established
biobank for human samples in AstraZeneca. He has
Rivka Ravid is a Tissue/Bio banker and a a PhD in genetics from the University of Gothenburg
neuroscientist. She is one of the pioneers of the (1986) and received post-doctoral training in cell biology
European Brain Banking Network (EBBN+BNE) and at the Ludwig Institute for Cancer Research (LICR; Stockholm Branch,
since 2001 has been the Director of the Netherlands 1988-1992). In 1993 he joined Pharmacia in Lund Sweden (later Pfizer) to
Brain Bank and a Scientific Project leader at the work on chemotherapy for prostate cancer. 1994 he took up a position in
Netherlands Institute for Brain Research, Amsterdam Discovery at Astra, Mölndal, Sweden (later AstraZeneca) working in the
and the Brain Net Europe. Presently she is busy with areas of diabetes, metabolic syndrome and applied proteomics. During
setting up new biobanks and enhancing public awareness of the need recent years he has focussed his efforts on the translational area, -
for human specimens for research. Rivka Ravid is also an expert on biomarkers, target validation using human material, molecular medicine,
the legal/ethical issues in Bio banking and pioneered the setting up and was the Director of Discovery Medicine for the Cardiovascular and
of an international Ethical Code of Conduct. She specialises in CNS Gastrointestinal Research Area in AstraZeneca 2006-2008. Since 2008 he
biomarker research for early diagnostics, based on specimens from is leading the AstraZeneca biobank of human samples, covering 10 R&D
living patients as well as rapid post-mortem autopsies. sites globally. The remit of the global biobank is to secure legal & ethical
compliance, harmonise processes & tools, provide biobanking facilities,
give input to policies and processes, share best practice and facilitate
exploitation of human samples globally.
INTERNATIONAL ADVISORY PANEL
Peter Riegman, Björn Dahllöf, Aleks Davis,
President, Global Biobank Head, Head of Biological Sample
ISBER AstraZeneca Management, Eli Lilly
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globalbiobanking.com

3. Conference Day One 28 September 2010
08.00 Registration and Coffee 12:20 Human Tissue in Oncology Research at AstraZeneca:
Enabling Decision Making
09.00 Pharma IQ Welcome and Chairperson’s Opening • Securing a supply of human tissue for research and
Address establishing a reliable network
• Adhering to legal, ethical and biosafety requirements
INCREASING OPERATIONAL EFFICIENCY AND • Ensuring sample quality
• Human tissue research enabling decision making:
PRODUCTIVITY THROUGH EFFECTIVE COMMUNICATION practical examples from discovery, early and late
AND COLLABORATION clinical development
Chris Womack, Principal Clinical Histopathologist,
09:10 KEYNOTE: Global Biobank Harmonisation: Practical AstraZeneca
Reality or Wishful Thinking?
• Facilitating the search for samples for multi-centre 13:00 Networking Lunch Break
cancer translational research in Europe
• Assessing the need for multi-centre research to allow 14:10 Biobanking Within the Walls of Pharma: An Eli Lilly
sample and data exchangeability Case Study
• Discussing QA and QC in today’s healthcare research • Reviewing the Combined Specimen Bank, an
biobanking industry-designed biobank and IT solution
• Evaluating internal vs external quality assurance • Discussing the challenges and potential solutions for
(EQA) sample collection
• Predicting the effects of EQA on overall biobank • Meeting the needs of discovery research to validate
quality and credibility targets in human models earlier
• Standardisation in tissue collections; locally and • Assessing when to partner with external sample
across networks resources
Peter Riegman, President, ISBER • Looking to the future: what’s next for the Lilly
Biobank?
09:50 Developing International Biobank Networking: When Aleks Davis, Head of Biological Sample Management,
1+1 is Greater Than 2 Eli Lilly
• Discussing the need for and scientific value of
biobank networks 14:50 Integrating Biobanking into Industry Biomarker
• Assessing the designs and common challenges with a Research to Improve Translational Medicine
biobank network • Building up dry ice logistic processes to have a
• Identifying both the potential basic services and reliable, convenient, robust and affordable solution
practical limitations of a network • Developing personalised medicine together with
• Case study: the Spanish model for biobank clinicians and today’s standard of care
networking • Accepting clinical realities in order to minimise risks
Manuel Morente, Head of Tumour Bank Unit, Spanish in clinical sample and data collection
National Cancer Centre • Anticipating the perspectives of both colleagues and
the management to meet tomorrow’s requirements
10:30 Networking Coffee Break Arndt Schmitz, Leader of Biobank, Bayer-Schering
11:00 Using Available Resources in Biobank-Industry 15:30 Networking Coffee Break
Partnerships to Improve Your Cost Recovery
• Reviewing the resources biobanks have available to 15:50 Ensuring Sample Quality and Integrity to Improve CNS-
them Biomarker Drug Discovery and Development
• Discussing how these resources can be utilised to • Reviewing the Standard Operating Procedures
their full advantage for specimen procurement, management,
• Highlighting how biobanks can help the preparation, dissemination and storage
pharmaceutical industry • Assessing the quality of the disseminated samples
• 2 Case Studies: a National and State partnership with • Producing a code of conduct for the social, ethical and
the pharmaceutical industry legal considerations
Heather Thorne, kConFab Manager, • Ensuring you have the right IT infrastructure,
Peter MacCallum Cancer Centre including proper electronic tracking systems
• Discussing safety procedures
MAINTAINING HIGH STANDARDS OF QUALITY AND • Successful case studies of biomarker-biobank alliances
Rivka Ravid, Senior Scientist and Advisor, Royal Dutch
INTEGRATING BIOBANKING INTO RESEARCH TO Academy of Sciences
ADVANCE INTERNATIONAL DRUG DEVELOPMENT
RESEARCH AND ENABLE DECISION MAKING 16:30 PANEL DISCUSSION: The Variations and Flexibility of
Informed Consent
11:40 From Patient to RNA: a Hospital’s Experience of How a • What does informed consent actually cover?
Biobank Can Help Research • How does it vary between countries?
• Collecting consistent and high-quality specimens • How can we handle unexpected situations under
• Storing tissues with intact morphology, proteins, DNA informed consent?
and RNA for use in research and diagnostics • Is it possible to create an international standardised
• Ensuring sample quality through specific initial form?
collection SOPs Panelists:
• Collecting ‘fresh’ frozen tissues for use as Peter Riegman, President, ISBER
high-quality RNA sources in research studies Andreas Koehler, Global Head Clinical
• Avoiding RNAse contamination in samples to ensure Pharmacogenetics, Boehringer-Ingelheim
preservation of specimen Chris Womack, Principal Clinical Histopathologist,
Aoife McDermott, Senior Medical Scientist, Adelaide AstraZeneca
and Meath Hospital
17:10 Chairperson’s Closing Remarks and Close of Day One
17:30-18:30 EVENING DRINKS RECEPTION
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globalbiobanking.com

4. Conference Day Two 29 September 2010
08.30 Registration and Coffee 12:20 Case Study: Building a Large-Scale National Biobank
for Sweden
09.00 Pharma IQ Welcome and Chairperson’s Opening • The opportunity: diverse projects in a nation with
Address strengths in population studies and health registries
Peter Riegman, President, ISBER • Creating a smart overall plan for a large-scale biobank
• Progressive build-up of capability and capacity: input,
storage, retrieval
SUPPORTING DRUG DEVELOPMENT AND NAVIGATING • Teething troubles: converting problems into opportunities
REGULATIONS TO IMPROVE THE QUALITY OF YOUR • Reviewing the progress so far
• Evaluating outcomes: how good is a biobank? How big
SERVICES AND SAMPLE should it be?
Mark Divers, Head of Biobank, Karolinska Institute
09:10 Biological Archiving in Discovery Research to Support
Drug Development 13:00 Networking Lunch Break
• Discussing the types of reagents and information that
should be archived SUPPORTING DRUG DEVELOPMENT AND NAVIGATING
• Ensuring data integrity and quality assurance REGULATIONS TO IMPROVE THE QUALITY OF YOUR
• Managing sample registration and distribution SERVICES AND SAMPLE
• Establishing secure storage and inventory
management 14:10 Implementing Informatics in a Multi-Centre Biobank to
Laurie Overton, Manager, Fermentation Facility, Improve Operating Efficiency
GlaxoSmithKline • A brief introduction to the MCRC biobank
• Identifying the need for effective informatics
09:50 Collection of Future Use Genomic Specimens in Global • Assessing the problems and solutions
Clinical Trials: Navigating Regulations, Requests for • Labelling and bar-coding biological samples
Changes in Sample Permissions and Tracking Final • Implementing a commercial LIMS package
Approved Sample Permissions • Discussing future developments and improvements
• Utilising future use specimens for pharmaceutical Jane Rogan, Biobank Business Manager, Manchester
companies Cancer Research Centre
• Reviewing pharmaceutical industry sampling
practices as published by the Industry 14:50 Staying on Track: Efficient Sample Management to
Pharmacogenomics Working Group (I-PWG) Improve Biobank Operating Efficiency
• Identifying variation in sample permissions allowed • Receiving, confirming and tracking new samples
from global Ethics Committees, IRBs and Health • Maintaining high quality standards for GLP samples
Authorities • Using a barcode system to enter new clinical samples
• Discussing issues with approvals to collect specimens • Systematically arranging biospecimens for storage
• Tracking sample permissions for global clinical trials • Sample logistics: internal and international shipping
Amelia Wall Warner, Head of Clinical of biological samples, analytical compounds and materials
Pharmacogenomics and Clinical Specimen • Ensuring correct disposal of biological samples
Management, Merck Research Laboratories Gerardo de Pierro, Sample Management and Logistics
Manager, Novartis
10:30 Networking Coffee Break
15:30 Networking Coffee Break
BIOBANK CASE STUDIES: DEVELOPING AN EFFECTIVE
INTERNATIONAL BIOBANK AND ACHIEVING YOUR FULL 15:50 Assessing Specimen Fitness for Purpose and Safe
Limits for Research
POTENTIAL OPERATING EFFICIENCY • Identifying pre-analytical variables affectingRNA from
frozen tissue, DNA from FFPE tissue and proteins
11:00 Case Study: Developing and Maintaining the • Discussing the practical minimum level of QA for
AstraZeneca Biobank tissue samples obtained from patients
• Assessing the challenges, changes and developments • Molecular-friendly fixatives: can we combine good
over the last 12 months morphology with the preservation of nucleic acids?
• Supporting drug discovery and development with • Maximising the use of samples by making derivatives
human biological samples from tissue and supplying only what is necessary
• Reviewing the AstraZeneca Human Biological Sample Gerry Thomas, Professor of Molecular Pathology,
Policy 2010 Imperial College London
• Discussing the ethical standards and governance
• Consolidating infrastructure to support business 16:40 The Significance of Stem Cells and Cell Therapy for
Global Biobanking: from Specialty to Necessity
needs Recent exciting developments in stem cell research
• Considering internal vs. external biobanking with build on several decades of research into
accessibility, control and costs in mind haematopoietic stem cells and their clinical
Björn Dahllöf, Global Biobank Head, AstraZeneca application in the form of bone marrow and cord blood.
New developments in therapies often focus on these
11:40 Developing Global DNA Banking to Support Drug stem cells types which offer resources that can deliver
Development human stem cells much more readily into laboratory
• Setting up an automated DNA banking facility and work while avoiding repeated consent and the licenses
efficient sample management required for storing human tissue. Using the UK Stem
• Discussing sample and data collection across global Cell Bank as an example, this presentation will address
clinical trials a range of the key scientific and practical challenges
• Assessing IT solutions to support DNA banking and stem cells present for the biobanking community.
sample analysis • Discussing the broad impacts of stem cells for research
• Evaluating lessons learned from PGx informed • Analysing what they mean for the future of biobanking
consent and data protection • Understanding the practical and ethical changes and
• Understanding the value and use of banked samples their potential impact on biobanking
Andreas Koehler, Global Head Clinical • Considering the challenges of mass stem cell storage
and when they must be addressed
Pharmacogenetics, Boehringer-Ingelheim Glyn Stacey, Director, UK Stem Cell Bank
17:10 Chairperson’s Closing Remarks and Close of Day One
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globalbiobanking.com

5. CD-ROM Sponsor Featured Exhibitor
Nexus Biosystems provides high-integrity solutions for demanding Life Liconic AG is a major manufacturer and supplier of automated storage
Science applications. From Sample Storage to Sample Analysis, Nexus systems and environmental chambers for small and large scale sample
provides high-performance products and services to high-value discovery storage. In 2009, Liconic successfully installed their first -80°C Storage
laboratories. Nexus provides the Universal Store line of Automated Biological System and have since installed several further systems which can
and Chemical Compound Sample Storage, for highly-modular and expandable offer capacities ranging from 1 million to 10 million samples. This offers
systems from -80°C, -20°C and ambient environments. Nexus manufactures an exceptionally high degree of reliability in this relatively new field of
and sells its’ XPeel Automated Seal-Removal Systems enabling highly- automated -80°C storage systems. Liconic provides solutions that eliminate
automated systems to run unattended. Nexus markets the Aurora Microplate repetitive tasks, by automating what have previously been manual processes,
Products for sensitive fluorescence and cellular-imaging applications in the implementing effective sample management, storage solutions.
world’s leading assay development and screening settings.
Liconic UK Ltd Phone: 0044 (0) 1618752542
European Office: Phone: +49 8171 380711 Warren Bruce Court Fax: 0044 (0) 1618752540
NEXUS Biosystems GmbH Fax: +49 8171 380712 Warren Bruce Road Mobile: 0044 (0) 7500214061
Alpenstrasse 76 Sales: sales@nexusbio.com Trafford Park Email: lco@liconic.co.uk
82538 Geretsried General Inquiry: info@nexusbio.com
Germany
Media Partners Who Should Attend?
Senior Vice President, Vice President, Executive
Director, Director, Associate Director, Head and
Manager from:
• Independent Biobanks
Sponsorship & Exhibition Opportunities • Pharmaceutical
• Biotech
Maximise Your Involvement: Sponsorship and Exhibition Opportunities
• Medical Research Institute
The Pharma IQ Global Biobanking 2010 conference will be the perfect • Academia
platform for service providers to meet senior-level decision makers in
the pharmaceutical/biopharmaceutical industry implementing specific • Related government officials
storage, IT, automation, CRO, sample processing, sample analysis,
coding and tracking solutions and services. Contact Pharma IQ to discuss In the following departments:
how to position your company in front of our participants who are keen
to learn more about today’s technologies and services including decision • Research & Development
makers and Heads of biobanks, biorepositories, tissue banks, DNA banks • Biobanking
and sample management from industry, research institutes, hospitals
• Biorepository
and academia.
• Biological Sample Management
To profile your company at this event please contact Gal Cohen on • Biosample Management
+44 207 368 9300 or email sponsorship@iqpc.co.uk
• Pharmacogenomics
• Pathology
About Pharma IQ
• Genomics
• Translational Medicine
• Personalised Medicine
• Lab Management
Become a member of Pharma IQ and receive complimentary access to
resources that will keep you at the forefront of industry change. • Inventory Management
You will receive access to our growing library of multi-media presentations • Molecular Technologies
from industry leaders, an email newsletter updating you on new content
• Biologics Research
that has been added, free aggregated news feed from over 1000 global
news sources tracking your industry and special member only discounts • Data Privacy/Protection/Security Officers
on events. • Quality Control and Quality Management
Become a member here:
• PI Department
Web: www.pharma-iq.com
Phone: +44 (0) 207 368 9300
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globalbiobanking.com

6. Global Biobanking 2O1O 5 WAYS TO REGISTER
Freephone: 0800 652 2363 or
+44 (0)20 7368 9300
To speed registration, please provide the priority code located on the mailing label or in the box below.
My registration code is:
Fax: +44 (0)20 7368 9301
PDFW
Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the registration code above to Post: your booking form to
inform us of any changes or to remove your details. IQPC Ltd. Anchor House, 15-19
Britten Street, London SW3 3QL
INDUSTRY RATES
Packages Register and Pay by Register and Pay by Register and Pay by Standard Price Online: www.globalbiobanking.com
28th May* 9th July* 13th August*
Email: enquire@iqpc.co.uk
Platinum Package SAVE £600 SAVE £500 SAVE £400 £3495 + VAT
Conference + 4 Workshops £2895+ VAT £2995 + VAT £3095 + VAT
Gold Package SAVE £500 SAVE £400 SAVE £300 £2996 + VAT
Conference + 3 Workshops** £2496 + VAT £2596 + VAT £2696 + VAT Join our Global Biobanking event on
Silver Package SAVE £400 SAVE £300 SAVE £200 £2497 + VAT http://events.linkedin.com/Global-Biobanking-2010/pub/288288
Conference + 2 Workshops** £2097+ VAT £2197 + VAT £2297 + VAT
Bronze Package SAVE £300 SAVE £200 SAVE £100 £1998 + VAT
Conference + 1 Workshop** £1698+ VAT £1798 + VAT £1898 + VAT Team Discounts*
Conference Only SAVE £200 SAVE £100 £1499 + VAT £1499 + VAT
£1299+ VAT £1399 + VAT
IQPC recognises the value of learning in teams. Groups of 3 or more
booking at the same time from the same company receive a 10%
ACADEMIC, NON-PROFIT and NATIONAL BIOBANKS RATES discount. 5 or more receive a 15% discount. 7 receive a 20% discount.
Register and Pay by Standard Price Only one discount available per person.
28th May
Platinum Package Conference + 4 Workshops SAVE £450
£1299 + VAT
£1749 + VAT Venue & Accommodation
VENUE:
Gold Package Conference + 3 Workshops** SAVE £400 £1499 + VAT Thistle Marble Arch
£1099 + VAT
Bryanston Street, Marble Arch, London W1H 7EH
Silver Package Conference + 2 Workshops** SAVE £350 £1249 + VAT Phone: 0871 376 9027 Fax: 0871 376 9127
£899 + VAT
ACCOMMODATION:
Bronze Package Conference + 1 Workshop** SAVE £300 £999 + VAT For Thistle Marble Arch Tel: +44 (0)871 376 9027 select option 1,
£699 + VAT
or email: reservationsadmin.marblearch@guoman.co.uk . Always
Conference Only SAVE £250 £749 + VAT quote promotional code GA1. Prices from £130 + vat including
£499 + VAT breakfast. Or for a further selection of London. hotels search
*To qualify for discounts, payments must be received by the early bird registration deadline. Early booking discounts are not valid in conjunction with any other offer. www.4cityhotels.com
UK VAT is charged at 17.5%. VAT Registration # GB 799225967
** Please select your choice of workshop(s) A 6B6C6D6 Free Online Resources
To claim a variety of articles, podcasts and other free resources please
Delegate Details visit www.globalbiobanking.com
Please photocopy for each additional delegate
6 Mr 6 Mrs 6 Miss 6 Ms 6 Dr 6 Other Digital Conference On CD-ROM
First Name Family Name A digital version of the conference proceedings, including all
presentations, is available to buy.
Job Title
6 I cannot attend the event, please send me the CD Rom priced at
Tel No. £599 plus VAT
Email Recent digital conferences available - £599 plus VAT each
6 Yes I would like to receive information about products and services via email 6 Biobanking 2009
Organisation 6 Compound Management 2009
Nature of business 6 Disposables for Biomanufacturing 2009
6 Cool Chain Europe 2010
Address
Postcode Country Please send me conference materials indicated above.
Telephone Fax I have filled out credit card details below
Approving Manager
For further information
Name of person completing form if different from delegate: Please call: 0207 368 9300
or email: knowledgebank@iqpc.co.uk.
Signature
I agree to IQPC’s cancellation, substitution and payment terms Terms and Conditions
Special dietary requirements: 6 Vegetarian 6 Non-dairy 6 Other (please specify) Please read the information listed below as each booking is subject to IQPC Ltd standard terms and conditions.
Return of this email will indicate that you accept these terms.
Please indicate if you have already registered by Phone 6 Fax 6 Email 6 Web 6
Payment Terms Upon completion and return of the registration form full payment is required no later than 5
Please note: if you have not received an acknowledgement before the conference, please call us to confirm your booking. business days from the date of invoice. Payment of invoices by means other than by credit card, or purchase
order (UK Plc and UK government bodies only) will be subject to a £49 (plus VAT) per delegate processing fee.
Payment must be received prior to the conference date. We reserve the right to refuse admission to the confer-
Payment Method ence if payment has not been received.
IQPC Cancellation, Postponement and Substitution Policy You may substitute delegates at any time by
providing reasonable advance notice to IQPC. For any cancellations received in writing not less than eight (8)
Total price for your Organisation: (Add total of all individuals attending): days prior to the conference, you will receive a 90% credit to be used at another IQPC conference which must
occur within one year from the date of issuance of such credit. An administration fee of 10% of the contract fee
Card Number: VISA 6 M/C 6 AMEX 6 will be retained by IQPC for all permitted cancellations. No credit will be issued for any cancellations occurring
within seven (7) days (inclusive) of the conference.
6666666666666666 In the event that IQPC cancels an event for any reason, you will receive a credit for 100% of the contract fee paid.
You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur within one
year from the date of cancellation.
Exp. Date: 6 6 6 6 Sec: 6 6 6 6
Conference code 13647.003
In the event that IQPC postpones an event for any reason and the delegate is unable or unwilling to attend in
on the rescheduled date, you will receive a credit for 100% of the contract fee paid. You may use this credit
for another IQPC event to be mutually agreed with IQPC, which must occur within one year from the date of
Name On Card: Signature: postponement.
Except as specified above, no credits will be issued for cancellations. There are no refunds given under any
circumstances.
Billing Address (if different from below):
IQPC is not responsible for any loss or damage as a result of a substitution, alteration or cancellation/postpone-
ment of an event. IQPC shall assume no liability whatsoever in the event this conference is cancelled, resched-
City/County/Postcode Cheque enclosed for: £ (Made payable to IQPC Ltd.) uled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any other event that renders
performance of this conference impracticable, illegal or impossible. For purposes of this clause, a fortuitous
event shall include, but not be limited to: war, fire, labour strike, extreme weather or other emergency.
Please note that while speakers and topics were confirmed at the time of publishing, circumstances beyond the
(Please quote 13647.003 with remittance advice) control of the organizers may necessitate substitutions, alterations or cancellations of the speakers and/or topics.
As such, IQPC reserves the right to alter or modify the advertised speakers and/or topics if necessary without any
IQPC Bank Details: HSBC Bank, 67 George Street, Richmond Surrey, TW9 1HG. Sort Code: 40-38-18 Account No: 51304143 Swift liability to you whatsoever. Any substitutions or alterations will be updated on our web page as soon as possible.
Code: MIDLGB2112V IBAN Code: GB59MIDL40381851304143
Account Name: International Quality & Productivity Centre Ltd. Discounts All ‘Early Bird’ Discounts require payment at time of registration and before the cut-off date in order
to receive any discount. Any discounts offered whether by IQPC (including team discounts) must also require
payment at the time of registration. All discount offers cannot be combined with any other offer
PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE